Indications
Targeting multiple major indications, including metastatic HR+/HER2- breast cancer, triple-negative breast cancer；
Non-small cell lung cancer, as well as various urological and gynecological tumors.
Development Progress
Entered Phase III clinical trials in China.
Indications
B-cell malignancies, autoimmune diseases.
Development Progress
Phase I dose-escalation trial in lymphoma completed, well-tolerated in lymphoma patients; efficacy demonstrated in relapse and resistant lymphoma patients.
Phase I/II clinical study for relapsed/refractory primary immune thrombocytopenia (ITP) has shown significant efficacy and well tolerated with favorable safety profile.
Planned initiation of a clinical study for Primary Sjögren's Syndrome (pSS).
mAb Drugs
ADC Drugs
